We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+35.9%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.87B
AUM Growth
+$747M
Cap. Flow
+$514M
Cap. Flow %
7.48%
Top 10 Hldgs %
39.61%
Holding
82
New
19
Increased
22
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$249M
2
MANE
Veradermics Inc
MANE
+$141M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
4
COAG
Hemab Therapeutics
COAG
+$99.4M
5
UTHR icon
United Therapeutics
UTHR
+$69.6M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$182M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$125M
3
AXSM icon
Axsome Therapeutics
AXSM
+$86.7M
4
IMVT icon
Immunovant
IMVT
+$66.6M
5
BBIO icon
BridgeBio Pharma
BBIO
+$62.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBIO
76
Crescent Biopharma
CBIO
$693M
– –
-453,686
Closed -$8.33M
JANX icon
77
Janux Therapeutics
JANX
$994M
– –
-1,187,290
Closed -$16.5M
LRMR icon
78
Larimar Therapeutics
LRMR
$400M
– –
-1,500,000
Closed -$6.75M
SLNO
79
DELISTED
Soleno Therapeutics
SLNO
– –
-1,078,710
Closed -$36.1M
TERN
80
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,073,877
Closed -$56.6M
XBI icon
81
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-10,000,000
Closed -$1.28B
BLLN
82
BillionToOne Inc
BLLN
$4.94B
– –
-50,000
Closed -$3.95M
1 2 3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Deep Track Capital held 82 positions worth $6.87B, up 12% from $6.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deep Track Capital deployed $514M of net new capital in Q2 2026, opening 19 new positions and adding to 22 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 825,000 shares worth $248M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $86.7M trimmed.

  • Deep Track Capital's largest Q2 2026 buy was Alnylam Pharmaceuticals: 825,000 shares worth $248M.
  • Deep Track Capital added most to Veradermics Inc in Q2 2026, an estimated $141M increase.
  • Deep Track Capital's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $86.7M.
  • Deep Track Capital fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $182M.
  • Deep Track Capital's ten largest holdings make up 40% of its $6.87B portfolio in Q2 2026.
  • Deep Track Capital opened 19 new positions and closed 15 in Q2 2026.
  • Deep Track Capital's portfolio value rose 12% quarter-over-quarter to $6.87B.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.